Introduction

Thiazolopyridazine derivatives comprise a broad range of structurally interesting substances that display a variety of medicinally interesting properties including activities against cancers1,2, microbes3,4, viruses5 and bacteria6, as well as antioxidant7, analgesic and pesticidal activities8,9. As a result of these important properties, thiazolopyridazines remain the focus of our continuing investigations aimed at developing new and green routes for the synthesis of novel fused nitrogen containing heterocycles10,11,12,13,14,15,16,17,18. Until now, several methods have been developed for the synthesis of fused thiazolopyridazines, most of which are targeted at the synthesis of thiazolo[4,5-d]pyridazines1,2,3,5, thiazolo[3,2-b]pyridazine19 and thiazolo[5,4-c]pyridazine6. In contrast, current methods to prepare thiazolo[4,5-c]pyridazines are much less well-developed20, and they suffer from some major deficiencies. Specifically, the only method devised for this purpose involves reaction of pyridazine-3-carboxamide derivatives with Lawesson’s reagent under reflux for 48 h, which forms mono-substituted thiazolo[4,5-c]pyridazines in only moderate yields (Scheme 1a)20.

Scheme 1
scheme 1

(a) Previous and (b) new route for synthesis of thiazolo[4,5-c]pyridazine derivatives.

Full size image

In the current study, we developed a novel and efficient green method for the synthesis members of a series o thiazolo[4,5-c]pyridazine derivatives. The new protocol, which involves cyclocondensation reactions between 4-thiazolidinones and 3-oxo-2-arylhydrazonopropanals utilizing a high pressure Q-Tube reactor, is simple and environmentally benign (Scheme 1b). In contrast to those utilizing microwave irradiation and conventional heating, processes carried out using the Q-Tube reactor employ a high pressures to promote organic reactions. Use of the Q-tube technique has many advantageous features21,22,23,24,25,26,27,28 including higher yields, clean products, lower energy costs, lower reaction times and higher reproducibility than those associated with conventional open flask and microwave approaches, and safer conditions than those utilized in conventional sealed pressure tube processes.

Results and Discussion

The initial phase of the current investigation, which was aimed at developing a new method for synthesis of thiazolo[4,5-c]pyridazine derivatives utilizing cyclocondensation reactions between 4-thiazolidinones and 3-oxo-2-arylhydrazonopropanals, concentrated on the preparation of 4-thiazolidinones. We observed that by using a slight modification of a two-step procedure described previously29, aromatic or heteroaromatic amines 1a-c react with chloroacetyl chloride 2 to form the corresponding chloroacetyl derivatives 3a-c, which can be transformed to the respective 4-thiazolidinones 4a–c by reaction with ammonium thiocyanate in ethanol or dioxane under pressurized conditions utilizing a Q-Tube reactor.

Next, reaction of the 2-(benzothiazol-2-ylimino)thiazolidin-4-one (4a) and 3-oxo-3-phenyl-2-(2-phenylhydrazono)propanal (5a) was used as a model to explore procedures and conditions for preparing the target thiazolo[4,5-c]pyridzines. We observed that stirring solutions of 4a (5 mmol) and 5a (5 mmol) in ethanol, dioxane, acetonitrile or DMF (15 mL) containing ammonium acetate or anhydrous sodium acetate (10 mmol) at atmospheric pressure and reflux for 12 h does not lead to formation of any products (Table 1, entries 1–4). In contrast, stirring a mixture of 4a (5 mmol), 5a (5 mmol) and ammonium acetate (10 mmol) in acetic acid (10 mL) at reflux for 4 h leads to production of thiazolo[4,5-c]pyridazine 7a in 43% yield (Table 1, entry 5). The structure of the product was assigned as being 7a rather than that of the thiazolo[4,5-b]pyridine 6 (Scheme 3) using spectrometric analysis. For example, the mass spectrum of the product showed that it has an exact mass of m/z 465.0717 that corresponds to the atomic composition of C25H15N5OS2. The 1H NMR spectrum of 7a in DMSO-d6 contains a set of resonances in the 7.21–8.00 ppm region associated with the pyridazine H-4 and fourteen aromatic protons and is devoid of a NH signal. Moreover, the 13C{1H} NMR, spectra of 7a contains 20 signals in addition to a characteristic carbonyl resonance at 191.88 ppm. Finally, X-ray crystallographic analysis of a related substance 7m (see Fig. 1 below) enabled unambiguous assignment of the structure of 7a.

Table 1 Optimization of reaction of 4-thiazolidinone 4a and arylhydrazonal 5a.
Full size table
Figure 1
figure 1

Plot of X-ray single crystallographic data collected for 7m. Mercury (version 4.3.1) (https://www.ccdc.cam.ac.uk/solutions/csd-system/components/mercury/) was used to create this figure.

Full size image

The mechanism of this cycloaddition process illustrated in Scheme 4 involves two successive condensation reactions. In the route, the enol formed from the 4-thiazolidinone 4 by acetic acid stimulated enolization adds to the aldehyde carbonyl carbon to generate adduct A which undergoes dehydration process to produce the corresponding alkylidene intermediate B. Next, a nucleophilic addition of the hydrazine NH moiety to the 4-thiazolidinone carbonyl carbon generates adduct C that undergoes dehydration to produce the thiazolo[4,5-c]pyridazine 7.

The observations made above encouraged a more detailed study of the cyclocondensation reaction in order to uncover ideal conditions for the efficient synthesis of thiazolo[4,5-c]pyridazine 7a, especially those that utilize a Q-tube pressure reactor. As mentioned above, Q-tube reactors are economic alternatives to expensive microwave (MW) systems in that they can be employed to promote high pressure chemical reactions safely. For comparison purposes, we first carried out reaction of 4-thiazolidinone 4a (2 mmol), arylhydrazonal 5a (2 mmol) and ammonium acetate (4 mmol) in acetic acid (4 mL) in a 10 mL MW tube which was irradiated at 125 °C (250 watt, 25 min). This process produces 7a in 65% yield (Table 1, entry 6). On the other hand, a larger scale reaction of [4a (5 mmol), 5a (5 mmol) and ammonium acetate (10 mmol) in acetic acid (10 mL)] conducted in a 35 mL borosilicate glass tube in a Q-tube reactor at 150 °C for 30 min forms 7a in a much higher 81% yield (Table 1, entry 7). The noticeable enhancement in the yield of this reaction when a Q-tube reactor is employed may in part be a consequence of the fact that a temperature higher than the boiling points of the solvent and reagents is used and this leads to increase the reaction rate30,31. In addition, the increased pressure achievable using a Q-tube reactor reduces the volume of the reaction, thus increasing the effective concentrations of the reactants and their collision frequency, so the competing degradations of the reactants is minimized, allowing more clean reaction pattern. After clearly demonstrating the effect of using the Q-tube reactor on the efficiency of the thiazolo[4,5-c]pyridazine forming reaction (Table 1, entry 7), we assessed the effects of additives and temperature on the process. The results showed that the use of anhydrous sodium acetate rather than ammonium acetate and acetic acid as solvent is optimal (Table 1, entry 9). Also, we observed that temperature plays a role in determining the efficiency of this reaction. Accordingly, reactions performed at 150, 160 and 170 °C lead to formation of 7a in 86, 92 and 98% respective yields, (Table 1, entries 9–11).

The substrate scope of the novel cyclocondensation reaction, conducted using the conditions described in entry 11 of Table 1, was explored next. An assortment of 4-thiazolidinones 4a-c, prepared by using the same sequence illustrated in Scheme 2, and several 3-oxo-2-arylhydrazonopropanals 5, containing electron-withdrawing or -donating groups on both aryl substituents were used for this purpose. The results depicted in Table 2 show that reactions between 4a−c and 5 produce the corresponding thiazolo[4,5-c]pyridazine derivatives 7a−u in high yields and, consequently, that the existence of either electron-donating or electron-withdrawing substituents on both aryl moieties in the arylhydrazonal substrate has no effect on the efficiency of the new cyclocondensation process. The thiazolo[4,5-c]pyridazine 7 m (Fig. 1), generated in this exploratory effort was used to carry out X-ray crystallographic analysis to prove the assigned structures to the products and show that only the (Z)-isomer of 6-(benzothiazol-2-ylimino)-1,6-dihydrothiazolo[4,5-c]pyridazine 7 is formed in the reactions.

Scheme 2
scheme 2

Synthesis of the 4-thiazolidinones 4a–c.

Full size image
Scheme 3
scheme 3

Reaction of 4-thiazolidinone 4a and arylhydrazonal 5a.

Full size image
Scheme 4
scheme 4

Plausible mechanistic pathway for the formation of thiazolo[4,5-c]pyridazine 7.

Full size image
Table 2 Q-tube [4 + 2] cyclocondensation reactions of 4-thiazolidinone 4a-c and arylhydrazonal 5.
Full size table

In vitro anti-cancer screening

Owing to the general propensity of thiazolopyridazine derivatives to display interesting properties, we have embrked on a program to assess potential biological activities of the substances synthesized using the process described above. In the preliminary phase of this effort, we evaluated the cytotoxic activities of 7a-u towards three human cancer cell lines including HCT-116 (colon cancer), MF-7 (breast cancer) and A549 (lung cancer), in addition to the normal human cell line MCF10A (breast cell line). This assessment was performed using the standard MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] colorimetric assay32,33, and utilizes doxorubicin as a reference anti-cancer agent34,35,36,37,38. For this purpose, three independent determinations were made using treatments with three concentrations (12.5, 25 and 50 μM) of 7a-u for a 48 h incubation period. Analysis of the results of the MTT assays gave thew IC50 values for 7a-u that are listed in Table 3 and Fig. 2. Inspection of the data shows that in comparison with doxorubicin the thiazolopyridazine derivatives have good to excellent cytotoxic activities against the tested cancer cell lines with IC50 in the range of 6.90–51.46 μM (vs. 11.26–23.47 μM for doxorubicin). While all of the tested substances display IC50 values in the ten micromolar range, several trends in their activities are worthy of brief mention. Firstly with respect to the MCF-7 cell line, 7c, 7 h, 7k and 7p show the highest cytotoxic activities with IC50 values 14.34, 10.39, 15.43 and 13.60 μM, respectively (vs. doxorubicin 19.35 μM), while compounds 7b, 7e, 7j, 7 l and 7n exhibits comparable IC50 to the reference drug. In addition, the results show that 7a-p, which contain benzothiazole moieties, have higher cytotoxicities than do 7q-s and 7t,u, which contain benzenesulfonamide and [5-(1-methyl-1H-indole-3-carbonyl)-2-phenyl-2H-[1,2,3]triazol-4-ylimino] moieties, respectively. Substituents on the 1-N-aryl group play a significant rule in governing cytotoxic activity, as highlighted by the fact that the presence of electron-withdrawing substituents enhance activity (F > NO2 > Cl) while electron-donating substituents on the N-aryl moiety lower activity (H > Me > OMe). Moreover, 7s which possesses a benzenesulfonamide moiety and NO2 (electron-withdrawing) substituent on the 1-N-aryl group displays higher cytotoxic activity (IC50 = 6.90 μM) than doxorubicin (IC50 = 11.26 μM), against the HCT-116 cell line. Also, 7q, 7r and 7u are potent against the HCT-116 cell line. Furthermore, the respective IC50 values of 7f-h against the A549 lung cancer cell line are 25.73, 24.13 and 22.96 μM respectively, which reflects the combined importance of the benzothiazole moiety and two electron-withdrawing substituents on the N-aryl moiety, along with the two fluorine substituents which show better cytotoxicity. In order to decide whether the cytotoxic characteristics of the synthesized compounds in this investigation, has no fatal cytotoxic effect on the normal human cells, and mostly selective to the cancer cells, the compounds showed the highest cytotoxic profile against the used cancer cell line like 7c, 7 h, 7k, 7p and 7s, are screened and evaluated utilizing the same procedure against the MCF-10A cell line (normal breast cell line). The obtained IC50 values for this non-malicious cell (MCF-10A), gave promising data since their values [7c (32.98 ± 1.11 μM), 7h (38.69 ± 1.85 μM), 7k (32.15 ± 1.47 μM), 7p (35.64 ± 0.87 μM), 7s (26.88 ± 1.59 μM)] were comparable or higher than IC50 (28.74 ± 1.38) of doxorubicin when it was applied to the same normal cell line.

Table 3 IC50 values (μM) for 7a-u towards human cancer cell lines.
Full size table
Figure 2
figure 2

IC50 (μM) of 7a-u towards human cancer cell lines.

Full size image

Conclusion

In summary, the study described above led to the development of an efficient Q-tube reactor based high-pressure protocol for synthesizing unprecedented series of thiazolo[4,5-c]pyridazines via [4 + 2] cyclocondensation reactions between 3-oxo-2-arylhydrazonopropanals and 4-thiazolidinones. The process has a high functional group tolerance and atom economy, and it is performed using simple, safe and environmentally compatible conditions. The synthesized thiazolopyridazines were shown to possess a potent cytotoxicities against MCF-7 (breast), HCT-116 (colon), and  A549 (lung) cancer cell lines. The next target of this study in the future, after obtaining these promising primary anticancer activity results, is to conduct more comprehensive studies to determine how the newly prepared thiazolopyridazine derivatives work to promote cell death (the mode of action) and to optimize biological activities.

Experimental

General

Melting points were recorded on a Griffin melting point apparatus and are uncorrected. IR spectra were recorded using KBr disks and a Jasco FT-IR-6300 spectrophotometer. 1H NMR (400 MHz) or (600 MHz) and 13C{1H} NMR (100 MHz) or (150 MHz) spectra were recorded at 25 °C using DMSO-d6 or (TFA-d) as solvents with TMS as an internal standard on a Bruker DPX 400 or 600 super-conducting NMR spectrometer. Chemical shifts (δ) are reported in ppm. Low-resolution electron impact mass spectra [MS (EI)] and high-resolution electron impact mass spectra [HRMS (EI)] were performed using a high resolution GC-MS (DFS) thermo spectrometer at 70.1 eV and a magnetic sector mass analyzer. Following the courses of reactions and checking homogeneity of products were performed using thin layer chromatography (TLC). The Q-Tube assisted reactions were performed in a Q-tube pressure monitor safe reactor from Q Labtech (distributed by Sigma-Aldrich), equipped with stainless steel adapter attached with pressure gauge (300 psi), high pressure adapter (180 psi), a needle adapter, a borosilicate glass pressure tube (35 mL), Teflon sleeve, a PTFE faced silicon septa and a catch bottle. The X-ray crystallographic data were collected by using a Bruker X8 Prospector at room temperature by using Cu- Kα radiation. The structures were solved by using direct methods and expanded using Fourier techniques. The non-hydrogen atoms were refined anisotropically. The structures were solved and refined using the Bruker SHELXTL Software Package (Structure solution program- SHELXS-97 and Refinement program- SHELXL-97)39. Data were corrected for the absorption effects using the multi-scan method (SADABS). The crystal image was created by the software Mercury (version 4.3.1)40. Compounds 3a-c and 4a-c were prepared according to literature procedures with slight modification in case of 4a-c29. The three human cancer cell lines including HCT-116 (colon cancer), MCF-7 (breast cancer) and A549 (lung cancer) were obtained from the American Type Culture Collection (ATCC).

General procedure for the preparation of 2-Chloro-N-(heteroaryl)acetamides 3a–c

Solutions of amines 1a–c (10 mmol) and chloroacetyl chloride 2 (1.12 g, 10 mmol) in chloroform (for 3a,b) or dioxane (for 3c) (50 mL) containing K2CO3 (15 mmol) were stirred at reflux for 10 h. The solutions were concentrated in vacuo giving residues that were diluted with water (100 mL) and filtered. The solid product is then washed with 5% NaHCO3 and subsequently with water, dried and crystallized from appropriate solvent to furnish pure 3a–c.

N-Benzothiazol-2-yl-2-chloroacetamide (3a)29

Recrystallized from EtOH as white crystals, yield: 96%, m.p. 145–146 °C; IR (KBr): 𝑣/cm−1 3348 (NH), 1665 (CO); 1H-NMR (600 MHz, DMSO-d6): δ = 4.47 (s, 2 H, CH2), 7.32 (t, J = 7.6 Hz, 1 H, Ar-H), 7.45 (t, J = 7.6 Hz, 1 H, Ar-H), 7.77 (d, J = 7.6 Hz, 1 H, Ar-H), 7.99 (d, J = 7.6 Hz, 1 H, Ar-H), 12.74 (s, 1 H, NH); 13C{1H} NMR (150 MHz, DMSO-d6): δ = 43.0 (CH2), 121.2, 122.3, 124.3, 126.7, 131.9, 148.9, 158.1, 166.4; MS (EI): m/z (%) 227 (M+ + 1, 5.60), 226 (M+, 26.40). HRMS (EI): m/z calcd. for C9H7ClN2OS (M+) 225.9962, found 225.9963.

2-Chloro-N-(4-sulfamoylphenyl)acetamide (3b)41

Recrystallized from EtOH as white crystals, yield: 95%, m.p. 216–217 °C; IR (KBr): 𝑣/cm−1 3328, 3211, 3132 (NH2, NH), 1689 (CO); 1H-NMR (600 MHz, DMSO-d6): δ = 4.31 (s, 2 H, CH2), 7.29 (s, 2 H, NH2), 7.75–7.81 (m, 4 H, Ar-H), 10.68 (s, 1 H, NH); 13C{1H} NMR (150 MHz, DMSO-d6): δ = 43.6 (CH2), 119.0, 126.8, 138.9, 141.4, 165.2; MS (EI): m/z (%) 249 (M+ + 1, 30.95), 248 (M+, 81.25). HRMS (EI): m/z calcd. for C8H9ClN2O3S (M+) 248.0017, found 248.0016.

2-Chloro-N-[5-(1-methyl-1H-indole-3-carbonyl)-2-phenyl-2H-[1,2,3]triazol-4-yl]acetamide (3c)

Recrystallized from dioxane as pale yellow crystal, yield: 93%, m.p. 218–219 °C; IR (KBr): 𝑣/cm−1 3232 (NH), 1691, 1615 (2CO); 1H-NMR (600 MHz, DMSO-d6): δ = 3.96 (s, 3 H, CH3), 4.53 (s, 2 H, CH2), 7.31–7.34 (m, 2 H, Ar-H), 7.50 (t, J = 7.2 Hz, 1 H, Ar-H), 7.58 (d, J = 7.2 Hz, 1 H, Ar-H), 7.63 (t, J = 7.6 Hz, 2 H, Ar-H), 8.17 (d, J = 7.6 Hz, 2 H, Ar-H), 8.37 (d, J = 7.2 Hz, 1 H, Ar-H), 8.81 (s, 1 H, indole C-H), 10.85 (s, 1 H, NH); 13C{1H} NMR (150 MHz, DMSO-d6): δ = 33.4 (CH3), 66.3 (CH2), 110.8, 113.1, 118.9, 121.6, 122.7, 123.3, 126.6, 128.3, 129.7, 136.4, 137.1, 138.7, 140.2, 145.1, 164.1, 179.1; MS (EI): m/z (%) 394 (M+ + 1, 22.87), 393 (M+, 64.08). HRMS (EI): m/z calcd. for C20H16ClN5O2 (M+) 393.0987, found 393.0986.

General Procedure for the Synthesis of 2-(Arylimino)thiazolidin-4-ones 4a–c

Borosilicate glass pressure tubes (35 mL) of the Labtech Q-tube were charged with 2-chloro-N-(heteroaryl or aryl)acetamides 3a–c (10 mmol) and ammonium thiocyanate (15 mmol) in absolute ethanol (15 mL) (for 4a,b) or dioxane (15 mL) (for 4c). A PTFE faced silicon septa was placed on the top of the tubes and the appropriate cap andpressure adapter were used. The mixtures were heated in an oil bath at 130 °C for 30 min. The course of each reaction was monitored by using TLC and GC/MS. The reaction mixtures were cooled to room temperature, and the formed solids were separated by filtration, washed with water and then recrystallized from the appropriate solvent.

(Z)-2-(Benzothiazol-2-ylimino)thiazolidin-4-one (4a)29

Recrystallized from an EtOH/dioxane (1:1) mixture pale yellow crystals, yield: 87%, m.p. 201–202 °C; IR (KBr): 𝑣/cm−1 3145 (NH), 1734 (CO); 1H-NMR (600 MHz, DMSO-d6): δ = 4.12 (s, 2 H, CH2), 7.39 (t, J = 7.6 Hz, 1 H, Ar-H), 7.51 (t, J = 7.6 Hz, 1 H, Ar-H), 7.85 (d, J = 7.6 Hz, 1 H, Ar-H), 8.01 (d, J = 7.6 Hz, 1 H, Ar-H), 12.35 (s, 1 H, NH); 13C{1H} NMR (150 MHz, DMSO-d6): δ =35.7 (CH2), 121.8, 122.4, 124.7, 126.8, 133.5, 151.3, 166.7, 169.3, 174.8; MS (EI): m/z (%) 250 (M+ + 1, 14.60), 249 (M+, 100). HRMS (EI): m/z calcd. for C10H7N3OS2 (M+) 249.0025, found 249.0025.

(Z)-4-(4-oxothiazolidin-2-ylideneamino)benzenesulfonamide (4b)41

Recrystallized from dioxane as beige crystals, yield: 94%, m.p. 245–246 °C; IR (KBr): 𝑣/cm−1 3358, 3271, 3199 (NH2, NH), 1676 (CO); 1H-NMR (600 MHz, DMSO-d6): δ = 4.04 (s, 2 H, CH2), 7.10–7.11 (m, 1 H, Ar-H), 7.33 (s, 2 H, NH2), 7.80–7.82 (m, 3 H, Ar-H), 11.94 (s, 1 H, NH); 13C{1H} NMR (150 MHz, DMSO-d6): δ =34.4 (CH2), 119.9, 121.7, 127.1, 139.6, 162.3, 174.2; MS (EI): m/z (%) 272 (M+ + 1, 24.92), 271 (M+, 100). HRMS (EI): m/z calcd. for C9H9N3O3S2 (M+) 271.0080, found 271.0079.

(Z)-2-[5-(1-methyl-1H-indole-3-carbonyl)-2-phenyl-2H-1,2,3-triazol-4-ylimino]thiazolidin-4-one (4c)

Recrystallized from dioxane/DMF mixture (3:1), as pale orange crystal, yield: 91%, m.p. 223–224 °C; IR (KBr): 𝑣/cm−1 3322 (NH), 1691 (CO); 1H-NMR (600 MHz, DMSO-d6): δ = 3.99 (s, 3 H, CH3), 4.34 (s, 2 H, CH2), 7.30–7.38 (m, 2 H, Ar-H), 7.52 (t, J = 7.2 Hz, 1 H, Ar-H), 7.61–7.67 (m, 3 H, Ar-H), 8.18 (d, J = 7.6 Hz, 2 H, Ar-H), 8.37 (d, J = 7.2 Hz, 1 H, Ar-H), 8.81 (s, 1 H, indole C-H), 11.86 (s, 1 H, NH); 13C{1H} NMR (150 MHz, DMSO-d6): δ = 33.4 (CH3), 36.8 (CH2), 111.0, 112.7, 113.3, 119.0, 121.5, 122.7, 123.4, 126.6, 128.5, 129.8, 137.2, 138.7, 140.4, 144.6, 164.4, 178.9; MS (EI): m/z (%) 417 (M+ + 1, 9.28), 416 (M+, 33.25). HRMS (EI): m/z calcd. for C21H16N6O2S (M+) 416.1050, found 416.1050.

General procedure for the preparation of thiazolo[4,5-c]pyridazine derivatives 7a-u

Borosilicate glass pressure tubes (35 mL) of the Labtech Q-tube were charged with 4-thiazolidinone 4a-c (5 mmol), arylhydrazonal 5 (5 mmol), anhydrous sodium acetate (10 mmol) and glacial acetic acid (10 mL). A PTFE faced silicon septa was placed on the top of each tube and the appropriate cap and pressure adapter were used. The mixtures were heated in an oil bath at 170 °C for 25 min. The progress of each reaction was monitored by using TLC and GC/MS. The mixtures were cooled to room temperature, and the formed solids were separated by filtration, washed with ethanol and recrystallized from the appropriate solvent (see below) to give the thiazolo[4,5-c]pyridazine derivatives 7a-u as pure products.

(Z)-{6-(Benzothiazol-2-ylimino)-1-phenyl-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}phenymethanone (7a)

Recrystallized from dioxane, deep orange crystal, yield: 2.25 g (98%), m.p. 242–243 °C; IR (KBr): 𝑣/cm−1 1700 (CO); 1H-NMR (600 MHz, DMSO-d6): δ = 7.22 (t, J = 7.2 Hz, 1 H, Ar-H), 7.35–7.38 (m, 2 H, Ar-H), 7.45 (t, J = 7.8 Hz, 2 H, Ar-H), 7.52 (t, J = 7.2 Hz, 1 H, Ar-H), 7.59 (t, J = 7.8 Hz, 2 H, Ar-H), 7.68–7.73 (m, 5 H, Ar-H), 7.78 (d, J = 7.2 Hz, 1 H, Ar-H), 8.00 (d, J = 7.2 Hz, 1 H, Ar-H); 13C{1H} NMR (150 MHz, DMSO-d6): δ = 115.9, 120.0, 121.2, 122.1, 124.3, 124.9, 126.4, 128.6, 128.8, 129.5, 130.2, 131.1, 132.7, 133.6, 137.0, 141.9, 151.0, 161.8, 166.9, 168.6, 191.9; MS (EI): m/z (%) 466 (M+ + 1, 15.12), 465 (M+, 45.25). HRMS (EI): m/z calcd. for C25H15N5OS2 (M+) 465.0713, found 465.0717.

(Z)-{6-(Benzothiazol-2-ylimino)-1-(4-chlorophenyl)-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}phenylmethanone (7b)

Recrystallized from dioxane/DMF mixture (1:2), as reddish orange crystal, yield: 2.45 g (99%), m.p. 260–261 °C; IR (KBr): 𝑣/cm−1 1700 (CO); 1H-NMR (600 MHz, TFA-d): δ = 7.57 (d, J = 7.8 Hz, 2 H, Ar-H), 7.61 (t, J = 7.8 Hz, 2 H, Ar-H), 7.70–7.76 (m, 4 H, Ar-H), 7.77–7.85 (m, 3 H, Ar-H), 7.94 (d, J = 8.4 Hz, 1 H, Ar-H), 8.06 (d, J = 8.4 Hz, 1 H, Ar-H), 8.21 (s, 1 H, pyridine- H4); 13C{1H} NMR (150 MHz, TFA-d): δ = 115.4, 118.9, 121.6, 125.2, 129.5, 130.85, 130.88, 131.6, 131.7, 132.6, 133.0, 136.6, 137.1, 137.96, 137.98, 138.1, 141.7, 170.2, 1 71.7, 174.5, 197.6; MS (EI): m/z (%) 501 (M+ + 2, 36.57), 500 (M+ + 1, 24.89), 499 (M+, 87.25). H RMS (EI): m/z calcd. for C25H14ClN5OS2 (M+) 499.0323, found 499.0323.

(Z)-{6-(Benzothiazol-2-ylimino)-1-(4-nitrophenyl)-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}phenylmethanone (7c)

Recrystallized from EtOH/DMF mixture (1:3), as reddish brown crystal, yield: 2.40 g (94%), m.p. 257–258 °C; IR (KBr): 𝑣/cm−1 1704 (CO); 1H-NMR (600 MHz, TFA-d): δ = 7.63 (t, J = 7.8 Hz, 2 H, Ar-H), 7.76–7.80 (m, 4 H, Ar-H  ), 7.83 (t, J = 8.4 Hz, 1 H, Ar-H), 7.95–7.99 (m, 3 H, Ar-H), 8.13 (d, J = 8.4 Hz, 1 H, Ar-H), 8.18 (s, 1 H, pyridine- H4), 8.51 (d, J = 7.8 Hz, 2 H, Ar-H); 13C{1H} NMR (150 MHz, TFA-d): δ = 118.7, 119.7, 125.5, 128.5, 129.7, 131.20, 131.24, 131.9, 133.2, 134.6, 136.1, 137.3, 137.9, 138.2, 147.5, 149.3, 170.1, 171.9, 173.9, 197.5; MS (EI): m/z (%) 511 (M+ + 1, 17.89), 510 (M+, 57.78). HRMS (EI): m/z calcd. for C25H14N6O3S2 (M+) 510.0563, found 510.0563.

(Z)-{6-(Benzothiazol-2-ylimino)-1-(4-methoxyphenyl)-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}phenylmethanone (7d)

Recrystallized from dioxane/DMF mixture (3:1), as reddish brown crystal, yield: 2.35 g (95%), m.p. 250–251 °C; IR (KBr): 𝑣/cm−1 1707 (CO); 1H-NMR (600 MHz, TFA-d): δ = 4.04 (s, 3 H, O-CH3), 7.24 (d, J = 9.0 Hz, 2 H, Ar-H), 7.59 (t, J = 7.8 Hz, 2 H, Ar-H), 7.67 (d, J = 7.8 Hz, 2 H, Ar-H), 7.70–7.74 (m, 2 H, Ar-H), 7.81 (t, J = 7.8 Hz, 1 H, Ar-H), 7.87 (d, J = 9.0 Hz, 2 H, Ar-H), 7.90 (d, J = 7.8 Hz, 1 H, Ar-H), 8.07 (d, J = 7.8 Hz, 1 H, Ar-H), 8.21 (s, 1 H, pyridine- H4); 13C{1H} NMR (150 MHz, TFA-d): δ = 58.1 (OCH3), 113.7, 118.3, 118.8, 122.6, 125.3, 129.5, 130.7, 130.8, 130.9, 131.7, 133.0, 136.4, 137.4, 138.00, 138.2, 139.0, 162.2, 170.4, 171.7, 174.5, 197.8; MS (EI): m/z (%) 496 (M+ + 1, 22.45), 495 (M+, 67.28). HRMS (EI): m/z calcd. for C26H17N5O2S2 (M+) 495.0818, found 495.0818.

(Z)-{6-(Benzothiazol-2-ylimino)-1-(4-chlorophenyl)-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}(4-chlorophenyl)methanone (7e)

Recrystallized from dioxane/DMF mixture (1:1), as reddish orange crystal, yield: 2.55 g (96%), m.p. above 300 °C; IR (KBr): 𝑣/cm−1 1705 (CO); 1H-NMR (600 MHz, TFA-d): δ = 7.41–7.44 (m, 4 H, Ar-H), 7.52 (d, J = 8.4 Hz, 2 H, Ar-H), 7.61–7.66 (m, 3 H, Ar-H), 7.70 (t, J = 8.4 Hz, 1 H, Ar-H), 7.80 (d, J = 8.4 Hz, 1 H, Ar-H), 7.92 (d, J = 8.4 Hz, 1 H, Ar-H), 8.02 (s, 1 H, pyridine- H4); 13C{1H} NMR (150 MHz, TFA-d): δ = 115.8, 119.0, 121.8, 125.3, 129.6, 131.0, 131.5, 132.2, 132.5, 132.7, 133.2, 136.6, 137.3, 137.4, 138.1, 141.8, 143.9, 170.3, 171.8, 174.5, 196.0; MS (EI): m/z (%) 535 (M+ + 2, 53.18), 534 (M+ + 1, 20.85), 533 (M+, 74.09). HRMS (EI): m/z calcd. for C25H13Cl2N5OS2 (M+) 532.9933, found 532.9934.

(Z)-{6-(Benzothiazol-2-ylimino)-1-(2-chloro-5-nitrophenyl)-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}(4-chlorophenyl)methanone (7 f)

Recrystallized from DMF, as reddish orange crystal, yield: 2.80 g (98%), m.p. above 300 °C; IR (KBr): 𝑣/cm−1 1711 (CO); 1H-NMR (600 MHz, TFA-d): δ = 7.51 (d, J = 8.4 Hz, 2 H, Ar-H), 7.63–7.66 (m, 3 H, Ar-H), 7.69–7.74 (m, 2 H, Ar-H), 7.82 (d, J = 8.4 Hz, 1 H, Ar-H), 8.07–8.09 (m, 2 H, Ar-H), 8.17 (d, J = 8.4 Hz, 1 H, Ar-H), 8.73 (d, J = 2.4 Hz, 1 H, Ar-H); 13C{1H} NMR (150 MHz, TFA-d): δ = 109.8, 115.2, 115.4, 120.3, 123.1, 126.8, 127.4, 128.7, 129.0, 129.2, 129.5, 130.6, 131.5, 132.1, 133.0, 134.8, 137.4, 140.9, 146.9, 166.6, 168.4, 168,8, 192.6; MS (EI): m/z (%) 580 (M+ + 2, 12.68), 579 (M+ + 1, 5.88), 578 (M+, 15.12). HRMS (EI): m/z calcd. for C25H12Cl2N6O3S2 (M+) 577.9784, found 577.9784.

(Z)-{6-(Benzothiazol-2-ylimino)-1-(2-chloro-5-nitrophenyl)-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}(4-bromophenyl)methanone (7 g)

Recrystallized from DMF, as reddish orange crystal, yield: 3.00 g (97%), m.p. above 264–265 °C; IR (KBr): 𝑣/cm−1 1715 (CO); 1H-NMR (600 MHz, TFA-d): δ = 7.64 (d, J = 8.4 Hz, 2 H, Ar-H), 7.74–7.83 (m, 5 H, Ar-H), 7.91 (d, J = 8.4 Hz, 1 H, Ar-H), 8.16–8.20 (m, 2 H, Ar-H), 8.26 (d, J = 8.4 Hz, 1 H, Ar-H), 8.88 (d, J = 2.4 Hz, 1 H, Ar-H); 13C{1H} NMR (150 MHz, TFA-d): δ = 112.9, 118.2, 118.4, 123.3, 126.0, 129.8, 130.4, 132.1, 132.2, 132.5, 133.6, 134.4, 134.8, 135.2, 136.4, 137.8, 140.5, 149.9, 167.0, 169.7, 171.6, 171.9, 196.0; MS (EI): m/z (%) 624 (M+ + 2, 100), 623 (M+ + 1, 31.89), 622 (M+, 69.75). HRMS (EI): m/z calcd. for C25H12BrClN6O3S2 (M+) 621.9279, found 621.9278.

(Z)-{6-(Benzothiazol-2-ylimino)-1-(2,4-difluorophenyl)-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}(4-bromophenyl)methanone (7 h)

Recrystallized from dioxane/DMF mixture (1:1), as orange crystal, yield: 2.70 g (94%), m.p. above 261–262 °C; IR (KBr): 𝑣/cm−1 1716 (CO); 1H-NMR (600 MHz, TFA-d): δ = 7.00–7.08 (m, 2 H, Ar-H), 7.50 (d, J = 8.4 Hz, 2 H, Ar-H), 7.65–7.68 (m, 3 H, Ar-H), 7.75 (t, J = 8.4 Hz, 1 H, Ar-H), 7.85 (d, J = 8.4 Hz, 1 H, Ar-H), 7.96 (d, J = 8.4 Hz, 1 H, Ar-H), 8.08–8.11 (m, 2 H, Ar-H); 13C{1H} NMR (150 MHz, TFA-d): δ = 107.7 (t, 2JCF = 24 Hz), 115.0 (dd, 2 JCF = 3.0, 24.0 Hz), 116.5, 119.0, 121.0 (d, 3JCF = 10.5 Hz), 125.3, 128.4 (dd, 3JCF = 4.5, 10.5 Hz), 129.6, 131.0, 132.0, 132.4, 132.5, 133.2, 135.2, 137.0 (d, 3JCF = 9.0 Hz), 138.1, 156.0 (dd, JCF = 12.0, 252.0 Hz), 163.9, 164.9 (dd, 1JCF = 12.0, 252.0 Hz), 170.2, 171.8, 174.3, 196.3; MS (EI): m/z (%) 581 (M+ + 2, 100), 580 (M+ + 1, 24.73), 579 (M+, 85.89). HRMS (EI): m/z calcd. for C25H12Br F2N5OS2 (M+) 578.9629, found 578.9628.

(Z)-{6-(Benzothiazol-2-ylimino)-1-p-tolyl-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}(4-fluorophenyl)methanone (7i)

Recrystallized from EtOH/DMF mixture (1:4), as red crystal, yield: 2.30 g (92%), m.p. 251–252 °C; IR (KBr): 𝑣/cm−1 1708 (CO); 1H-NMR (600 MHz, TFA-d): δ = 2.31 (s, 3 H, CH3), 7.08 (t, J = 7.8 Hz, 2 H, Ar-H), 7.24 (d, J = 7.8 Hz, 2 H, Ar-H), 7.55–7.60 (m, 5 H, Ar-H), 7.67 (d, J = 7.8 Hz, 1 H, Ar-H), 7.76 (d, J = 7.8 Hz, 1 H, Ar-H), 7.83 (d, J = 7.8 Hz, 1 H, Ar-H), 7.98 (s, 1 H, pyridine- H4); 13C{1H} NMR (150 MHz, TFA-d): δ = 22.5 (CH3), 119.06, 119.11, 119.2, 120.8, 125.2, 129.7, 130.7, 130.9, 133.6, 134.1 (d, 3JCF = 9 Hz), 134.7, 138.3 (d, 2JCF = 24 Hz), 140.8, 143.5, 169.2 (d, 3JCF = 10 Hz), 170.4, 171.7, 174.7, 195.8; MS (EI): m/z (%) 498 (M+ + 1, 27.12), 497 (M+, 100.00). HRMS (EI): m/z calcd. for C26H16FN5OS2 (M+) 497.0775, found 497.0775.

(Z)-{6-(Benzothiazol-2-ylimino)-1-(4-chlorophenyl)-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}(naphthalen-1-yl)methanone (7j)

Recrystallized from dioxane/DMF mixture (1:1), as red crystal, yield: 2.60 g (96%), m.p. 254–255 °C; IR (KBr): 𝑣/cm−1 1708 (CO); 1H-NMR (600 MHz, TFA-d): δ = 7.49–7.52 (m, 3 H, Ar-H), 7.59 (t, J = 7.2 Hz, 1 H, Ar-H), 7.63 (d, J = 7.8 Hz, 1 H, Ar-H), 7.69–7.72 (m, 3 H, Ar-H), 7.77–7.93 (m, 5 H, Ar-H), 7.98 (d, J = 7.2 Hz, 1 H, Ar-H), 8.16–8.21 (m, 2 H, Ar-H); 13C{1H} NMR (150 MHz, TFA-d): δ = 115.4, 118.8, 121.5, 125.0, 125.7, 129.4, 130.20, 130.22, 130.8, 131.5, 131.7, 131.9, 132.0, 132.5, 132.9, 133.2, 134.8, 135.1, 136.9, 137.7, 137.9, 138.4, 141.6, 170.0, 171.4, 174.3, 196.9; MS (EI): m/z (%) 551 (M+ + 2, 45.28), 550 (M+ + 1, 33.08), 549 (M+, 100.00). HRMS (EI): m/z  calcd. for C29H16ClN5OS2 (M+) 549.0479, found 549.0478.

(Z)-{6-(Benzothiazol-2-ylimino)-1-(4-nitrophenyl)-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}(naphthalen-1-yl)methanone (7k)

Recrystallized from dioxane/DMF mixture (1:1), as red crystal, yield: 2.65 g (95%), m.p. 263–264 °C; IR (KBr): 𝑣/cm−1 1708 (CO); 1H-NMR (600 MHz, TFA-d): δ = 7.61–7.64 (m, 3 H, Ar-H), 7.70 (d, J = 7.2 Hz, 1 H, Ar-H), 7.80 (t, J = 7.8 Hz, 1 H, Ar-H), 7.84–7.87 (m, 2 H, Ar-H), 7.93–8.03 (m, 5 H, Ar-H), 8.15 (t, J = 7.2 Hz, 2 H, Ar-H), 8.53 (d, J = 9.0 Hz, 2 H, Ar-H); 13C{1H} NMR (150 MHz, TFA-d): δ = 119.0, 120.0, 121.7, 123.8, 125.3, 125.4, 126.9, 128.4, 128.5, 129.2, 129.7, 130.2, 131.1, 132.4, 133.1, 135.2, 136.3, 138.0, 140.4, 147.6, 150.6, 154.1, 169.7, 171.6, 173.0, 173.7, 199.5; MS (EI): m/z (%) 561 (M+ + 1, 30.17), 560 (M+, 100.00). HRMS (EI): m/z calcd. for C29H16N6O3S2 (M+) 560.0720, found 560.0720.

(Z)-{ 6-(Benzothiazol-2-ylimino)-1-(4-nitrophenyl)-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}(naphthalen-2-yl)methanone (7 l)

Recrystallized from dioxane/DMF mixture (1:1), as red crystal, yield: 2.60 g (93%), m.p. 259–260 °C; IR (KBr): 𝑣/cm−1 1704 (CO); 1H-NMR (600 MHz, TFA-d): δ = 7.56 (t, J = 7.8 Hz, 1 H, Ar-H), 7.63 (t, J = 7.8 Hz, 1 H, Ar-H), 7.72 (d, J = 8.4 Hz, 1 H, Ar-H), 7.75 (t, J = 7.8 Hz, 1 H, Ar-H), 7.81 (t, J = 8.4 Hz, 1 H, Ar-H), 7.87 (d, J = 7.8 Hz, 1 H, Ar-H), 7.90–7.94 (m, 4 H, Ar-H), 7.98 (d, J = 8.4 Hz, 1 H, Ar-H), 7.10 (d, J = 8.4 Hz, 1 H, Ar-H), 8.22 (s, 1 H, Ar-H), 8.27 (s, 1 H, Ar-H), 8.45 (d, J = 9.0 Hz, 2 H, Ar-H); 13C{1H} NMR (150 MHz, TFA-d): δ = 118.6, 119.0, 125.3, 125.7, 128.4, 129.6, 130.3, 131.1, 131.7, 132.1, 132.4, 133.1, 133.8, 134.7, 134.9, 135.9, 138.1, 138.7, 147.3, 149.2, 169.9, 171.6, 173.7, 196.8; MS (EI): m/z (%) 561 (M+ + 1, 30.78), 560 (M+, 100.00). HRMS (EI): m/z calcd. for C29H16N6O3S2 (M+) 560.0720, found 560.0720.

(Z)-{6-(Benzothiazol-2-ylimino)-1-phenyl-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}(thiophen-2-yl)methanone (7 m)

Recrystallized from EtOH/DMF mixture (1:2), as reddish brown crystal, yield: 2.15 g (92%), m.p. above 300 °C; IR (KBr): 𝑣/cm−1 1713 (CO); 1H-NMR (600 MHz, TFA-d): δ = 7.33 (t, J = 4.8 Hz, 1 H, Ar-H), 7.62 (t, J = 7.8 Hz, 1 H, Ar-H), 7.73 (t, J = 7.8 Hz, 1 H, Ar-H), 7.82 (t, J = 8.4 Hz, 2 H, Ar-H), 7.88–7.90 (, 3 H, Ar-H), 8.07 (d, J = 4.8 Hz, 1 H, Ar-H), 8.11 (d, J = 8.4 Hz, 2 H, Ar-H), 8.53 (d, J = 4.8 Hz, 1 H, Ar-H), 9.29 (s, 1 H, pyridine-H4); 13C{1H} NMR (150 MHz, TFA-d): δ = 117.5, 124.7, 127.4, 128.5, 129.4, 129.7, 131.5, 132.0, 132.2, 134.6, 137.2, 139.3, 142.6, 143.7, 143.8, 147.5, 151.1, 162.4, 170.2, 180.4, 182.0; MS (EI): m/z (%) 472 (M+ + 1, 28.88), 471 (M+, 100.00). HRMS (EI): m/z calcd. for C23H13N5OS3 (M+) 471.0277, found 471.0276. Crystal Data, moiety formula: C23H13N5OS3, M = 471.56, monoclinic, a = 13.8134(7) Å, b = 9.7580(5) Å, c = 16.2524(7) Å, V = 2089.17(18) Å3, α = γ = 90°, β = 107.510(3)°, space group: P 21/n, Z = 4, Dcalc = 1.499 g·cm−3, No. of reflection measured 3515, θ max = 66.76°, R1 = 0.0756 (CCDC 1969668)42.

(Z)-{6-(Benzothiazol-2-ylimino)-1-(4-chlorophenyl)-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}(thiophen-2-yl)methanone (7n)

Recrystallized from DMF, as reddish brown crystal, yield: 2.35 g (93%), m.p. above 300 °C; IR (KBr): 𝑣/cm−1 1714 (CO); 1H-NMR (600 MHz, TFA-d): δ = 7.23 (t, J = 4.8 Hz, 1 H, Ar-H), 7.53 (t, J = 7.8 Hz, 1 H, Ar-H), 7.63 (t, J = 7.8 Hz, 1 H, Ar-H), 7.71 (d, J = 7.8 Hz, 1 H, Ar-H), 7.75–7.78 (m, 3 H, Ar-H), 7.97 (d, J = 4.8 Hz, 1 H, Ar-H), 8.00 (d, J = 9.0 Hz, 2 H, Ar-H), 8.40 (d, J = 4.8 Hz, 1 H, Ar-H), 9.14 (s, 1 H, pyridine-H4); 13C{1H} NMR (150 MHz, TFA-d): δ = 117.7, 124.9, 128.4, 128.9, 129.5, 129.9, 131.6, 132.1, 132.5, 137.3, 139.3, 141.6, 142.2, 142.6, 143.7, 147.9, 151.1, 162.5, 170.4, 180.9, 182.1; MS (EI): m/z (%) 507 (M+ + 2, 42.08), 506 (M+ + 1, 23.95), 505 (M+, 100.00). HRMS (EI): m/z calcd. for C23H12ClN5OS3 (M+) 504.9887, found 504.9889.

(Z)-{6-(Benzothiazol-2-ylimino)-1-(2-chloro-5-nitrophenyl)-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}(furan-2-yl)methanone (7o)

Recrystallized from EtOH/DMF mixture (1:2), as reddish brown crystal, yield: 2.40 g (90%), m.p. 273–274 °C; IR (KBr): 𝑣/cm−1 1716 (CO); 1H-NMR (600 MHz, TFA-d): δ = 6.82 (t, J = 4.8 Hz, 1 H, Ar-H), 7.71–7.74 (m, 3 H, Ar-H), 7.81 (t, J = 8.4 Hz, 1 H, Ar-H), 7.91–7.92 (m, 2 H, Ar-H), 8.11 (d, J = 9.0 Hz, 1 H, Ar-H), 8.22 (d, J = 8.4 Hz, 1 H, Ar-H), 8.69 (d, J = 2.4 Hz, 1 H, Ar-H), 8.78 (s, 1 H, pyridine-H4); 13C{1H} NMR (150 MHz, TFA-d): δ = 112.9, 116.6, 118.7, 119.3, 123.5, 126.5, 127.8, 130.2, 130.8, 132.3, 133.0, 134.0, 134.1, 135.0, 138.2, 140.8, 150.3, 152.9, 153.2, 170.0, 171.8, 172.2, 179.8; MS (EI): m/z (%) 536 (M+ + 2, 14.22), 535 (M+ + 1, 9.89), 534 (M+, 28.92). HRMS (EI): m/z calcd. for C23H11ClN6O4S2 (M+) 533.9966, found 533.9965.

(Z)-{6-(Benzothiazol-2-ylimino)-1-(4-nitrophenyl)-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}(1-methyl-1H-indol-2-yl)methanone (7p)

Recrystallized from DMF, as deep orange crystal, yield: 2.55 g (91%), m.p. above 300 °C; IR (KBr): 𝑣/cm−1 1700 (CO); 1H-NMR (600 MHz, TFA-d): δ = 4.40 (s, 3 H, CH3), 7.98–8.98 (m, 14 H, Ar-H); 13C{1H} NMR (150 MHz, TFA-d): δ = 35.7 (CH3), 113.6, 116.9, 118.9, 119.1, 119.7, 124.1, 125.5, 127.6, 128.3, 128.5, 129.7, 131.3, 133.2, 135.7, 138.0, 138.2, 141.3, 143.57, 146.3, 150.0 , 170.0, 171.8, 173.8, 187.0, 188.1; MS (EI): m/z (%) 564 (M+ + 1, 2.24), 563 (M+, 7.85). HRMS  (EI): m/z calcd. for C28H17N7O3S2 (M+) 563.0829, found 563.0829.

(Z)-4-{3-Benzoyl-1-phenylthiazolo[4,5-c]pyridazin-6(1H)-ylideneamino}benzenesulfonamide (7q)

Recrystallized from  dioxane/DMF mixture (3:1), as orange crystal, yield: 2.20 g (91%), m.p. 251–252 °C; IR (KBr): 𝑣/cm−1 1699 (CO); 1H-NMR (600 MHz, DMSO-d6): δ = 7.00–7.98 (m, 17 H, 15Ar-H and SO2NH2); 13C{1H} NMR (150 MHz, DMSO-d6): δ = 115.6, 118.7, 120.3, 121.8, 123.2, 124.4, 127.0, 128.6, 128.8, 129.4, 130.1, 130.9, 132.8, 136.9, 140.2, 141.8, 172.0, 191.9; MS (EI): m/z (%) 488 (M+ + 1, 28.75), 487 (M+, 100.00). HRMS (EI): m/z calcd. for C24H17N5O3S2 (M+) 487.0757, found 487.0769.

(Z)-4-{3-(4-Chlorobenzoyl)-1-(4-chlorophenyl)thiazolo[4,5-c]pyridazin-6(1H)-ylideneamino}benzenesulfonamide (7r)

Recrystallized from dioxane/DMF mixture (1:1), as orange crystal, yield: 2.60 g (94%), m.p. 244–245 °C; IR (KBr): 𝑣/cm−1 1699 (CO); 1H-NMR (600 MHz, TFA-d): δ = 7.39–7.43 (m, 4 H, 2Ar-H and SO2NH2), 7.60–7.65 (m, 6 H, Ar-H), 7.88 (d, J = 8.4 Hz, 2 H, Ar-H), 8.22 (s, 1 H, pyridine-H4), 8.35 (d, J = 8.4 Hz, 2 H, Ar-H); 13C{1H} NMR (150 MHz, TFA-d): δ = 111.8, 121.2, 128.2, 130.8, 131.4, 132.0, 132.1, 132.4, 136.1, 137.2, 139.0, 140.3, 141.0, 143.8, 145.6, 168.7, 177.2, 195.9; MS (EI): m/z (%) 557 (M+ + 1, 71.89), 556 (M+ + 1, 28.63), 555 (M+, 100.00). HRMS (EI): m/z calcd. for C24H15Cl2N5O3S2 (M+) 554.9988, found 554.9986.

(Z)-4-{3-Benzoyl-1-(4-nitrophenyl)-1H-thiazolo[4,5-c]pyridazin-6-ylideneamino}benzenesulfonamide (7 s)

Recrystallized from dioxane/DMF mixture (2:1), as pale orange crystal, yield: 2.45 g (92%), m.p. 249–250 °C; IR (KBr): 𝑣/cm−1 1700 (CO); 1H-NMR (600 MHz, TFA-d): δ = 7.39–7.43 (m, 4 H, 2Ar-H and SO2NH2), 7.62 (d, J = 7.2 Hz, 2 H, Ar-H), 7.68 (d, J = 7.2 Hz, 2 H, Ar-H), 7.75 (t, J = 7.2 Hz, 2 H, Ar-H), 7.88 (d, J = 8.4 Hz, 2 H, Ar-H), 8.25–8.27 (m, 2 H, Ar-H and pyridine-H4), 8.34 (d, J = 8.4 Hz, 2 H, Ar-H); 13C{1H} NMR (150 MHz, TFA-d): δ = 111.4, 121.0, 128.0, 130.4, 130.9, 131.2, 131.3, 132.2, 136.3, 136.9, 137.6, 139.4, 140.1, 140.8, 145.4, 168.5, 177.0, 197.4; MS (EI): m/z (%) 533 (M+ + 1, 27.82), 532 (M+, 100.00). HRMS (EI): m/z calcd. for C24H16N6O5S2 (M+) 532.0618, found 532.0617.

(Z)-{6-[5-(1-Methyl-1H-indole-3-carbonyl)-2-phenyl-2H-[1,2,3]triazol-4-ylimino]-1-phenyl-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}phenylmethanone (7t)

Recrystallized from EtOH/DMF mixture (1:2), as yellow crystal, yield: 2.75 g (88%), m.p. 292–293 °C; IR (KBr): 𝑣/cm−1 1698, 1665 (2CO); 1H-NMR (600 MHz, TFA-d): δ = 4.01 (s, 3 H, CH3), 7.17 (t, J = 7.8 Hz, 1 H, Ar-H), 7.23 (d, J = 7.2 Hz, 2 H, Ar-H), 7.29 (t, J = 7.8 Hz, 2 H, Ar-H), 7.34–7.40 (m, 2 H, Ar-H), 7.49–7.51 (m, 3 H, Ar-H), 7.55–7.57 (m, 3 H, Ar-H), 7.68 (t, J = 7.2 Hz, 1 H, Ar-H), 7.85 (d, J = 7.2 Hz, 1 H, Ar-H), 8.13 (d, J = 7.8 Hz, 2 H, Ar-H), 8.19 (d, J = 7.8 Hz, 2 H, Ar-H), 8.95 (s, 1 H, in dole C-H), 9.19 (s, 1 H, pyridine-H4); 13C{1H} NMR (150 MHz, TFA-d): δ = 36.5 (CH3), 114.6, 115.21, 122.8, 124.9, 127.4, 128.2, 128.6, 129.3, 131.1, 131.7, 132.3, 132.8, 133.4, 133.6,  134.1, 135.5, 136.0, 137.9, 140.9, 141.4, 142.1, 142.4, 146.4, 149.8, 151.1, 157.7, 162.6, 162.9, 194.1; MS (EI): m/z (%) 633 (M+ + 1, 3.25), 632 (M+, 10.54). HRMS (EI): m/z calcd. for C36H24N8O2S (M+) 632.1737, found 632.1737.

(Z)-{1-(4-Chlorophenyl)-6-[5-(1-methyl-1H-indole-3-carbonyl)-2-phenyl-2H-[1,2,3]triazol-4-ylimino]-1,6-dihydrothiazolo[4,5-c]pyridazin-3-yl}phenylmethanone (7 u)

Recrystallized from EtOH/DMF mixture (1:3), as yellow crystal, yield: 2.95 g (89%), m.p. 295–296 °C; IR (KBr): 𝑣/cm−1 1699, 1662 (2CO); 1H-NMR (600 MHz, TFA-d): δ = 4.08 (s, 3 H, CH3), 7.21–7.26 (m, 3 H, Ar-H), 7.29 (d, J = 8.4 Hz, 2 H, Ar-H), 7.45 (d, J = 7.8 Hz, 1 H, Ar-H), 7.55–7.58 (m, 3 H, Ar-H), 7.61–7.64 (m, 3 H, Ar-H), 7.75 (t, J = 7.8 Hz, 1 H, Ar-H), 7.89 (d, J = 7.8 Hz, 1 H, Ar-H), 8.18 (d, J = 8.4 Hz, 2 H, Ar-H), 8.25–8.27 (m, 2 H, Ar-H), 8.99 (s, 1 H, pyridine-H4), 9.27 (s, 1 H, indole C-H); 13C{1H} NMR (150 MHz, TFA-d): δ = 36.3 (CH3), 114.5, 115.0, 122.7, 124.7, 128.0, 128.4, 128.6, 129.1, 131.0, 131.7, 132.2, 133.4, 134.0, 135.4, 135.8, 137.8, 139.2, 140.66, 140.74, 141.2, 142.0, 146.3, 149.7, 151.1, 157.6, 162.1, 162.6, 171.0, 193.8; MS (EI): m/z (%) 668 (M+ + 2, 3.45), 667 (M+ + 1, 4.67), 666 (M+, 7.41). HRMS (EI): m/z calcd. for C36H23ClN8O2S (M+) 666.1348, found 666.1344.

MTT in vitro cytotoxic assay

The in vitro cytotoxic activities of 7a-u were determined toward three human cancer cell lines including HCT-116 (colon cancer), MCF-7 (breast cancer) and A549 (lung cancer), and one normal cell MCF10A (breast cell), by employing the MTT colorimetric assay. The cell lines were grown in a MEM (Minimum Essential Media) medium boosted with 10% fetal bovine serum (FBS), penicillin, and streptomycin at 37 °C in 5% CO2 humidified atmosphere. The tested compounds were dissolved in DMSO and the resulting solutions were diluted by adding culture medium to the required concentrations. Each cell line was distributed into 96 well sterilized plates in a medium boosted with 10% FBS then treated with the three concentrations of the tested compounds and doxorubicin. In all cases, the incubation time was 48 h in 5% CO2 incubator at 37 °C. Then the medium was removed and a solution of MTT was added and the mixture was incubated again for 4 h. After incubation, the MTT solution was removed and the obtained purple formazan dye was dissolved in DMSO. Finally the absorbance at 490 nm was measured utilizing a microplate spectrophotometer and triplicate experiments were carried out. The IC50 values (Table 3) were calculated using the GraphPad Prism Scientific graphing explore software version 7.0.

Supporting Information

  • 1H NMR, 13C{1H} NMR, MS, and HRMS spectra for the reported compounds (PDF).

  • Crystal data for compound 7 m (CIF).